CR6706A - Pirido (2,3-d) pirimidin-2-7-diaminas inhibidores de cinasas - Google Patents

Pirido (2,3-d) pirimidin-2-7-diaminas inhibidores de cinasas

Info

Publication number
CR6706A
CR6706A CR6706A CR6706A CR6706A CR 6706 A CR6706 A CR 6706A CR 6706 A CR6706 A CR 6706A CR 6706 A CR6706 A CR 6706A CR 6706 A CR6706 A CR 6706A
Authority
CR
Costa Rica
Prior art keywords
compounds
substituted
unsubstituted
pirido
diamins
Prior art date
Application number
CR6706A
Other languages
English (en)
Inventor
Myra Dobrusin Ellen
Prasad Venkata Nagendra Josyula Vara
John Booth Richard
Joseph Mcnamara Dennis
Laurence Toogood Peter
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of CR6706A publication Critical patent/CR6706A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Consiste en compuestos de formula en la cual R2, R7, R13, y R15, son independientemente, hidrogeno o alquilo inferior sustituido o sin sustituir, alquenilo inferior sustituido o sin sustituir, alquinilo inferior sustituido o sin sustituir, o bien -(CH2) nR112 sustituido o sin sustituir y otros compuestos. Estos compuestos y sus composiciones farmaceuticas son utiles para tratar trastornos proliferativos celulares, tales como cancer y restenosis. Estos compuestos son potentes inhibidores de cdks y de cinasas mediadas por factor de crecimiento.
CR6706A 2000-01-25 2002-07-17 Pirido (2,3-d) pirimidin-2-7-diaminas inhibidores de cinasas CR6706A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17826100P 2000-01-25 2000-01-25

Publications (1)

Publication Number Publication Date
CR6706A true CR6706A (es) 2005-04-04

Family

ID=22651853

Family Applications (1)

Application Number Title Priority Date Filing Date
CR6706A CR6706A (es) 2000-01-25 2002-07-17 Pirido (2,3-d) pirimidin-2-7-diaminas inhibidores de cinasas

Country Status (34)

Country Link
EP (1) EP1254137A1 (es)
JP (1) JP4047010B2 (es)
KR (1) KR20020065939A (es)
CN (1) CN1395578A (es)
AP (1) AP2002002586A0 (es)
AR (1) AR030044A1 (es)
AU (1) AU2542501A (es)
BG (1) BG106850A (es)
BR (1) BR0107751A (es)
CA (1) CA2397961C (es)
CO (1) CO5261549A1 (es)
CR (1) CR6706A (es)
CZ (1) CZ20022475A3 (es)
DZ (1) DZ3266A1 (es)
EA (1) EA200200643A1 (es)
EE (1) EE200200405A (es)
GT (1) GT200100016A (es)
HN (1) HN2001000013A (es)
HU (1) HUP0204141A3 (es)
IL (1) IL150545A0 (es)
IS (1) IS6443A (es)
MA (1) MA26868A1 (es)
MX (1) MXPA02007221A (es)
NO (1) NO20023527L (es)
OA (1) OA12161A (es)
PA (1) PA8510701A1 (es)
PE (1) PE20011066A1 (es)
PL (1) PL356802A1 (es)
SK (1) SK10632002A3 (es)
SV (1) SV2002000294A (es)
TN (1) TNSN01014A1 (es)
WO (1) WO2001055147A1 (es)
YU (1) YU50402A (es)
ZA (1) ZA200205879B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
CN100525768C (zh) 2000-10-23 2009-08-12 史密丝克莱恩比彻姆公司 新化合物
PE20030008A1 (es) * 2001-06-19 2003-01-22 Bristol Myers Squibb Co Inhibidores duales de pde 7 y pde 4
KR20040103972A (ko) 2002-04-19 2004-12-09 스미스클라인 비참 코포레이션 신규 화합물
JP2006508997A (ja) * 2002-11-28 2006-03-16 シエーリング アクチエンゲゼルシャフト Ｃｈｋ−、Ｐｄｋ−およびＡｋｔ−阻害性ピリミジン、それらの製造および薬剤としての使用
US7157455B2 (en) * 2003-02-10 2007-01-02 Hoffmann-La Roche Inc. 4-Aminopyrimidine-5-one derivatives
TW200502236A (en) 2003-03-28 2005-01-16 Hoffmann La Roche Novel pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents
FR2873118B1 (fr) 2004-07-15 2007-11-23 Sanofi Synthelabo Derives de pyrido-pyrimidine, leur application en therapeutique
CA2579406A1 (en) * 2004-09-21 2006-03-30 F.Hoffmann-La Roche Ag 6-(2-alkyl-phenyl) - pyrido[2,3-d] pyrimidines useful as protein kinase inhibitors
US20080096905A1 (en) 2005-03-25 2008-04-24 Glaxo Group Limited Process For Preparing Pyrido[2,3-D]Pyrimidin-7-One And 3,4-Dihydropyrimido{4,5-D}Pyrimidin-2(1H)-One Derivatives
PE20061193A1 (es) 2005-03-25 2006-12-02 Glaxo Group Ltd DERIVADOS DE 3,4-DIHIDROPIRIMIDO[4,5-d]PIRIMIDIN-2-[1H]-0NA COMO INHIBIDORES DE QUINASA p38
US7423042B2 (en) 2005-03-25 2008-09-09 Glaxo Group Limited Compounds
MY145343A (en) 2005-03-25 2012-01-31 Glaxo Group Ltd Novel compounds
FR2887882B1 (fr) * 2005-07-01 2007-09-07 Sanofi Aventis Sa Derives de pyrido[2,3-d] pyrimidine, leur preparation, leur application en therapeutique
ES2336603T3 (es) * 2005-07-21 2010-04-14 F. Hoffmann-La Roche Ag Compuestos de pirido(2,3-d)pirimidina-2,4-diamina como inhibidores de ptp1b.
WO2007021795A2 (en) * 2005-08-09 2007-02-22 Irm Llc Compounds and compositions as protein kinase inhibitors
FR2896246B1 (fr) 2006-01-13 2008-08-15 Sanofi Aventis Sa Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique.
EP1914234A1 (en) 2006-10-16 2008-04-23 GPC Biotech Inc. Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors
JO2985B1 (ar) 2006-12-20 2016-09-05 Takeda Pharmaceuticals Co مثبطات كينازmapk/erk
FR2910813B1 (fr) 2006-12-28 2009-02-06 Sanofi Aventis Sa Nouvelle utilisation therapeutique pour le traitement des leucemies
EP2112150B1 (en) 2008-04-22 2013-10-16 Forma Therapeutics, Inc. Improved raf inhibitors
CN102216299B (zh) * 2008-12-01 2015-02-11 默克专利有限公司 作为自体毒素抑制剂的2,5-二氨基取代的吡啶并[4,3-d]嘧啶化合物
GB201104267D0 (en) 2011-03-14 2011-04-27 Cancer Rec Tech Ltd Pyrrolopyridineamino derivatives
GB201216018D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Pharmacologically active compounds
GB201216017D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Inhibitor compounds
US9815847B2 (en) 2013-03-14 2017-11-14 Icahn School Of Medicine At Mount Sinai Pyrimidine compounds as kinase inhibitors
GB201403536D0 (en) 2014-02-28 2014-04-16 Cancer Rec Tech Ltd Inhibitor compounds
KR101671404B1 (ko) * 2014-09-02 2016-11-02 한국원자력의학원 항암 효과, 방사선 병용치료 효과 및 당뇨병 치료 효과를 갖는 피리미딘 유도체 및 이의 의학적 용도
CN107286180B (zh) * 2016-04-11 2019-07-02 上海勋和医药科技有限公司 杂代吡啶并嘧啶酮衍生物作为cdk抑制剂及其应用
GB201709840D0 (en) 2017-06-20 2017-08-02 Inst Of Cancer Research: Royal Cancer Hospital Methods and medical uses

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL115256A0 (en) * 1994-11-14 1995-12-31 Warner Lambert Co 6-Aryl pyrido (2,3-d) pyrimidines and naphthyridines and their use
PL181893B1 (pl) * 1994-11-14 2001-10-31 Warner Lambert Co Zwiazki bedace pochodnymi pirymidyny i naftyrydyny oraz preparat farmaceutyczny zawierajacy je PL PL PL
US5620981A (en) * 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
TR200003429T2 (tr) * 1998-05-26 2001-07-23 Warner-Lambert Company Hücresel çoğalma inhibitörleri olarak bisiklik pirimidinler ve bisiklik 3,4-dihidropirimidinler.

Also Published As

Publication number Publication date
SK10632002A3 (sk) 2003-06-03
HUP0204141A2 (hu) 2003-04-28
SV2002000294A (es) 2002-07-16
GT200100016A (es) 2001-10-19
EA200200643A1 (ru) 2002-12-26
ZA200205879B (en) 2003-09-29
AP2002002586A0 (en) 2002-09-30
PL356802A1 (en) 2004-07-12
KR20020065939A (ko) 2002-08-14
IL150545A0 (en) 2003-02-12
EP1254137A1 (en) 2002-11-06
OA12161A (en) 2006-05-08
NO20023527D0 (no) 2002-07-24
AU2542501A (en) 2001-08-07
BR0107751A (pt) 2002-11-12
DZ3266A1 (fr) 2001-08-02
CA2397961C (en) 2008-08-26
CA2397961A1 (en) 2001-08-02
HN2001000013A (es) 2001-06-18
HUP0204141A3 (en) 2005-03-29
WO2001055147A1 (en) 2001-08-02
JP2003523357A (ja) 2003-08-05
NO20023527L (no) 2002-09-10
AR030044A1 (es) 2003-08-13
MA26868A1 (fr) 2004-12-20
YU50402A (sh) 2005-11-28
PE20011066A1 (es) 2001-10-22
CZ20022475A3 (cs) 2003-03-12
IS6443A (is) 2002-06-25
CN1395578A (zh) 2003-02-05
JP4047010B2 (ja) 2008-02-13
CO5261549A1 (es) 2003-03-31
TNSN01014A1 (fr) 2005-11-10
PA8510701A1 (es) 2002-12-11
EE200200405A (et) 2003-12-15
MXPA02007221A (es) 2002-11-29
BG106850A (bg) 2003-02-28

Similar Documents

Publication Publication Date Title
CR6706A (es) Pirido (2,3-d) pirimidin-2-7-diaminas inhibidores de cinasas
CR6736A (es) 5-alquilpirido[2,3-d[ piridinas como inhibidores de tirosina kinasa
BRPI0507644A (pt) pirazolopirimidinas como inibidores de cinase dependente de ciclina
ES2192877T3 (es) 4-alquenil (y alquinil) oxindoles como inhibidores de kinasas ciclina-dependientes, en particular cdk2.
TW200407311A (en) N-substituted tricyclic 3-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders
GEP20125658B (en) Imidazotriazines and imidazo pyrimidines as kinase inhibitors
MY139355A (en) Compounds and methods for inhibiting mitotic progression by inhibition of aurora kinase
IL173348A0 (en) Thienopyridine and furopyridine kinase inhibitors
TW200510380A (en) Mitotic kinesin inhibitors
CR9219A (es) Derivados de triazol sustituidos como antagonistas de oxitocina
YU61402A (sh) Pirol substituisani 2 indolinon protein kinazni inhibitori
UY27234A1 (es) Inhibidores novedosos de tirosina cinasa
ECSP078062A (es) Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen
GEP20125368B (en) Kinase inhibitors
MXPA05011296A (es) Conjugados de fosfonato inhibidores de la cinasa.
BRPI0511975A (pt) pirazolopirimidinas
ATE554087T1 (de) Neue kinaseinhibitoren
MXPA05013076A (es) Compuestos de isoindolina-1-ona como inhibidores de cinasa.
TN2009000329A1 (fr) DERIVES DE 2-AMINO-5,7-DIHYDRO-6H-PYRROLO[3,4-d]-PYRIMIDINE SERVANT D'INHBITEURS DE HSP-90 POUR LE TRAITEMENT DU CANCER
MXPA05009151A (es) Inhibidores de cinasa heterociclica.
CR9579A (es) Inhibidores de tirosina quinasa
PA8613001A1 (es) Derivados de triazol sustituidos como antagonistas de oxitocina
ECSP034776A (es) Indolinonas sustituidas en posicion 6, su preparacion y su utilizacion como medicamentos
AR026037A1 (es) Indolinonas sustituidas en posicion 5, su preparacion y su utilizacion como medicamentos
DE60100539D1 (en) Tosylprolin-derivate als thymidylat-synthase inhibitoren

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)